Treace Medical Concepts, Inc. (TMCI) Earnings Call Transcripts

Treace Medical Concepts, Inc.'s Latest Earnings Call - Q1 FY2026

In the first quarter of 2026, Treace Medical Concepts, Inc. (TMCI) reported revenue of $47.2 million, reflecting a 10% decline year-over-year, primarily due to a shift towards lower-priced minimally invasive products. The company reaffirmed its full-year guidance, projecting revenue between $202 million and $212 million, indicating a potential decline of 5% to flat compared to 2025. Management expressed optimism about future growth, particularly in the fourth quarter, driven by new product launches and increasing case volumes.

Reported metrics

Guidance from management

Treace reaffirmed its full-year revenue guidance of $202 million to $212 million, indicating a decline of 5% to flat compared to 2025. They expect revenue declines to improve in the fourth quarter, supported by new product launches and increasing case volumes.

What management said

Sorry, this is Mark. I think another important point to realize is that as we've offered these new product options, we don't necessarily believe that they're replacing our Lapiplasty procedures as well. We think it's going to be additive and allow them to have more options for the patient needs. So where that ultimately lands, what that mix ultimately is, it's still to be determined, but we don't necessarily believe...

Yes, Ben, we tried to do this in a very capital-efficient and inventory efficient way. As we thought about launching a compression screw system, we didn't want to have high capital, high inventory burden. Traditionally, these systems are -- have a lot of SKUs, hundreds and hundreds, maybe 1,000. So we've been trying -- we've tried to design this and bring forth a system that, I don't have the exact number of SKUs, b...

What analysts pressed on

Analysts expressed concerns regarding the ongoing impact of ASP-related mix shifts on revenue and the potential for continued declines in the first half of 2026. There were questions about the competitive landscape and how new product launches would affect market share moving forward.

Main topics on the call

• Revenue Decline — Treace reported a revenue decline of approximately 10% in Q1 2026, attributed to a mix shift towards lower-priced products. Management stated, "We believe this trend will improve over time as we annualize the launch of t...
• Product Launches and Market Penetration — The company introduced three new bunion systems in 2025, which have seen adoption by 35% of its Lapiplasty surgeon user base. John Treace noted, "We believe these 3 new systems more than double our accessible market rela...
• Gross Margin Stability — Gross margin for Q1 2026 was reported at 79.3%, slightly down from 79.7% in the previous year. Mark Hair commented, "We're pleased with what we did in Q1. They came in strong, a little bit better than what we had anticip...
• Cash Burn Reduction — Management highlighted a meaningful reduction in cash burn, moving towards cash flow breakeven. They expect a reduction in cash usage of approximately 50% for the full year 2026 compared to 2025.

Read the full Treace Medical Concepts, Inc. transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 36 Treace Medical Concepts, Inc. earnings call transcripts on record, spanning May 25, 2021 to August 7, 2026. Based on this history, Treace Medical Concepts, Inc. reports quarterly. The most recent call on file is dated August 7, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

TMCI

Exchange

NasdaqGS

Country

US

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

36

First call

May 25, 2021

Most recent

August 7, 2026

Reporting cadence

quarterly